53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM–CHK2–P53 pathway
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Purpose Loss of P53 binding protein 1 (53BP1) is considered a poor prognostic factor for colorectal cancer. However, its effect on chemosensitivity of colorectal cancer to 5-fluorouracil (5-FU) remains elusive. This study aimed to examine the association of 53BP1 expression with chemosensitivity of colorectal cancer cells to 5-FU.Methods Immunohistochemistry was performed on 30 metastatic colorectal cancer samples to assess the associations of 53BP1 levels with clinical therapeutic effects. In vitro, IC 50 values for 5-FU and 53BP1 levels were determined by MTT assay and Western blot in 5 colorectal cancer cell lines. Then, 53BP1 was silenced in HCT116 and HT29 cells, and cell proliferation, apoptosis and cell cycle distribution were evaluated. Relative protein levels of ATM-CHK2-P53 pathway effectors and Bcl-2 family members were measured by Western blot. Finally, the effects of 53BP1 knockdown on tumor growth and 5-FU chemoresistance were investigated in vivo.Results 53BP1 expression was closely related to time to progression (TTP) after first-line chemotherapy. Namely, 53BP1 downregulation resulted in reduced TTP. In addition, 53BP1 silencing increased proliferation, inhibited apoptosis and induced S phase arrest in HCT116 and HT29 cells after 5-FU treatment. Moreover, 53BP1 knockdown also reduced the protein levels of ATM-CHK2-P53 apoptotic pathway effectors, caspase9 and caspase3, while increasing Bcl-2 expression. In vivo, 53BP1 silencing accelerated tumor proliferation in nude mice and enhanced resistance to 5-FU.Conclusions These findings confirmed that 53BP1 loss might be a negative factor for chemotherapy efficacy, promoting cell proliferation and inhibiting apoptosis by suppressing ATM-CHK2-P53 signaling, and finally inducing 5-FU resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a tumor suppressor gene, P53 mutation could disrupt DNA-damage-induced cell cycle arrest and inhibit tumor cell apoptosis, which could induce chemotherapy resistance in various solid tumors, including CRC [256,257].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [257]
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging
O'Connell, J. B., Maggard, M. A., & Ko, C. Y. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh275 · Cited by 1,599
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Self-citationFolprecht, G., Gruenberger, T., Bechstein, W. O., Raab, H.-R., Lordick, F., Hartmann, J. T., Lang, H., Frilling, A., Stoehlmacher, J., Weitz, J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70330-4 · Cited by 963
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Two cellular proteins that bind to wild-type but not mutant p53.
Iwabuchi, K., Bartel, P. L., Li, B., Marraccino, R., & Fields, S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.6098 · Cited by 431
Squatrito, M., Brennan, C. W., Helmy, K., Huse, J. T., Petrini, J. H., & Holland, E. C. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.034 · Cited by 238
Push back to respond better: regulatory inhibition of the DNA double-strand break response
Panier, S., & Durocher, D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3659 · Cited by 170
European cancer mortality predictions for the year 2011
Malvezzi, M., Arfè, A., Bertuccio, P., Levi, F., Vecchia, C. L., & Negri, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq774 · Cited by 136
Bártková, J., Hořejší, Z., Sehested, M., Nesland, J. M., Meyts, E. R., Skakkebæk, N. E., Stucki, M., Jackson, S. P., Lukáš, J., & Bártek, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210553 · Cited by 128
Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin
Shi, Y., Felley-Bosco, E., Marti, T. M., Orlowski, K., Pruschy, M., & Stahel, R. A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-571 · Cited by 124
RNF168 ubiquitylates 53BP1 and controls its response to DNA double-strand breaks
Bohgaki, M., Bohgaki, T., El Ghamrasni, S., Srikumar, T., Maire, G., Panier, S., Fradet-Turcotte, A., Stewart, G. S., Raught, B., Hakem, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320302111 · Cited by 99
53BP1 and p53 synergize to suppress genomic instability and lymphomagenesis
Morales, J. C., Franco, S., Murphy, M. M., Bassing, C. H., Mills, K. D., Adams, M. M., Walsh, N. C., Manis, J. P., Rassidakis, G. Z., Alt, F. W., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511259103 · Cited by 88
53BP1 Cooperates with p53 and Functions as a Haploinsufficient Tumor Suppressor in Mice
Ward, I. M., Difilippantonio, S., Minn, K., Mueller, M. D., Molina, J. R., Yu, X., Frisk, C. S., Ried, T., Nussenzweig, A., & Chen, J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10079-10086.2005 · Cited by 87
Pan, S., Cheng, L., White, J. T., Lu, W., Utleg, A. G., Yan, X. S., Urban, N. D., Drescher, C. W., Hood, L., & Lin, B. (2009) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2009.0008 · Cited by 86
Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression
Nuciforo, P. G., Luise, C., Capra, M., Pelosi, G., & d'Adda di Fagagna, F. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm108 · Cited by 80
Adam, R. A., Haller, D. G., Poston, G. J., Raoul, J., Spano, J., Tabernero, J. M., & Cutsem, E. V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq043 · Cited by 79
Knappskog, S., Chrisanthar, R., Løkkevik, E., Anker, G. B., Østenstad, B., Lundgren, S., Risberg, T., Mjaaland, I., Leirvaag, B., Miletić, H., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3147 · Cited by 74
Y-27632, a ROCK Inhibitor, Promoted Limbal Epithelial Cell Proliferation and Corneal Wound Healing
Sun, C., Chiu, H.-T., Lin, Y.-F., Lee, K.-Y., & Pang, J. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144571 · Cited by 72
Lysine methylation-dependent binding of 53BP1 to the pRb tumor suppressor
Carr, S. M., Munro, S., Zalmas, L., Fedorov, O., Johansson, C., Krojer, T. J., Sagum, C. A., Bedford, M. T., Oppermann, U. C. T., & Thangue, N. B. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403737111 · Cited by 55
53BP1 functions as a tumor suppressor in breast cancer via the inhibition of NF-κB through miR-146a
Li, X., Xu, B., Moran, M. S., Zhao, Y., Su, P., Haffty, B. G., Shao, C., & Yang, Q. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs298 · Cited by 52
Self-citationAberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer
Bártková, J., Guldberg, P., Grønbæk, K., Koed, K., Primdahl, H., Møller, K., Lukas, J., Orntoft, T. F., & Bártek, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207878 · Cited by 49
Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma
Tanos, R., Karmali, D., Nalluri, S., & Goldsmith, K. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2129-0 · Cited by 40
Chiu, Y., Liu, J., Tang, K.-D., Wong, Y.-C., Khanna, K. K., & Ling, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051108 · Cited by 37
Bi, J., Huang, A., Liu, T., Zhang, T., & Ma, H. (2015) · Europe PMC (PubMed Central) · Cited by 34
Self-citationNeboori, H. J., Haffty, B. G., Wu, H., Yang, Q., Aly, A., Goyal, S., Schiff, D. S., Moran, M. S., Golhar, R., Chen, C., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.01.089 · Cited by 31
Self-citationRybanská, I., Reynolds, T. L., Chou, J., Prakash, M., Jefferson, T., Huso, D. L., Desiderio, S. V., & Franco, S. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0252-t · Cited by 26
Hepatitis B virus induces hypoxia-inducible factor-2α expression through hepatitis B virus X protein
Hu, J., LIU, L.-P., Yang, S., Fang, X., Wen, L., Ren, Q., & Yu, C. (2015) · Oncology Reports · doi:10.3892/or.2015.4480 · Cited by 23
Santarosa, M., & Maestro, R. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9336-6 · Cited by 22
Expression of 53BP1 as a cisplatin-resistant marker in patients with lung adenocarcinomas
Ho, S.-P. (2010) · Oncology Reports · doi:10.3892/or_00000862 · Cited by 20
Clarke, A. R., Jones, N., Pryde, F. E., Adachi, Y., & Sansom, O. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210457 · Cited by 15
Lockney, N. A., Wang, T., Wentz, S. C., Washington, M. K., Merchant, N. B., Zhao, Z., Shyr, Y., Chakravarthy, A. B., & Xia, F. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-155 · Cited by 15
Haffty, B. G., Goyal, S., Kulkarni, D. A., Green, C., Vazquez, A., Schiff, D. S., Moran, M. S., Yang, Q., Ganesan, S., & Hirshfield, K. M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.02.005 · Cited by 12
Self-citationTanaka, K., Saigusa, S., Toiyama, Y., Koike, Y., Okugawa, Y., Yokoe, T., Inoue, Y., Kobayashi, M., Miki, C., & Kusunoki, M. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22123 · Cited by 11
Ma, H., Bi, J., Liu, T., Yang, K., Zhang, S., & Zhang, T. (2014) · Oncology Reports · doi:10.3892/or.2014.3699 · Cited by 11
Self-citation
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
The molecular mechanisms of chemoresistance in cancers
Zheng, H.-C. (2017) · Oncotarget · doi:10.18632/oncotarget.19048 · Cited by 624
Guo, P., Tian, Z., Kong, X., Yang, L., Shan, X., Dong, B., Ding, X., Jing, X., Jiang, C., Jiang, N., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01677-w · Cited by 209
Azwar, S., Seow, H. F., Abdullah, M., Faisal Jabar, M., & Mohtarrudin, N. (2021) · Biology · doi:10.3390/biology10090854 · Cited by 173
Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Cao, X., Hou, J., An, Q., Assaraf, Y. G., & Wang, X. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100671 · Cited by 172
Metadata
- Authors
- Yao, J., Huang, A., Zheng, X., Liu, T., Lin, Z., Zhang, S., Yang, Q., Zhang, T., & Ma, H.
- Affiliations
- Wuhan Union Hospital (CN)
- Corresponding author
- Ma, Hong
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2016-11-12
- Volume
- 143
- Issue
- 3
- Pages
- 419-431
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- PMC
- PMC11819077
- OpenAlex
- W2553527471
- Cited by
- 52
- References
- 35
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 8 · 2021: 4 · 2020: 6 · 2019: 7 · 2018: 5 · 2017: 4
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Cancer Research and Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- 53BP1, colorectal cancer, 5-fluorouracil, chemoresistance, apoptosis, cell proliferation, S phase arrest, Bcl-2, caspase-3, caspase-9, time to progression, tumor growth
- MeSH terms
- Tumor Suppressor p53-Binding Protein 1, Animals, DNA Damage, DNA Repair, Fluorouracil, Humans, Colorectal Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Cell Proliferation, Mice, Ataxia Telangiectasia Mutated Proteins, Checkpoint Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.